Home
Medicamen Biotech Ltd Share Price History
Medicamen Biotech Ltd
NSE : 09 Apr, 2025
495.652.5 (0.5%)
Prev Close
493.2
Open Price
488.0
Bid Price (QTY)
-
Offer Price (QTY)
-
Volume
98514
Today's High / Low
501.6 / 471.4
52 WK High / Low
630.0 / 375.0
Market Price of Medicamen Biotech Ltd
1M
1Y
3Y
5Y
Monitoring Medicamen Biotech Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.
History Market Price
| Date | Price | Open | High | Low |
|---|
Returns Comparison
1W
1M
3M
6M
1Y
3Y
5Y
10Y
Growth Parameters
| Parameter |  2019 |
|---|---|
| Sales (Cr.) | NaN |
| Sales YoY Gr. | - |
| Adj EPS | 10.28 |
| YoY Gr. | - |
| Net Profit (Cr.) | 12 |
| BVPS | 74.05 |
Key Financial Parameters
| Parameter | 2019 |
|---|---|
| Return on Capital Emp. % | 19.03 |
| Op. Profit Mgn % | 17.23 |
| Net Profit Mgn % | 9.81 |
| Debt to Equity % | 0.14 |
Latest Shareholding
Promoters Holdings Over Time
About Medicamen Biotech Ltd
- A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
- The Company has presence in 40+ countries.
- Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
- MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
- The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.
Popular Search
FAQs for Medicamen Biotech Ltd Share Price History
What are the key events that typically impact Medicamen Biotech Ltd's share price history?
Key events that impact Medicamen Biotech Ltd’s share price history include quarterly earnings releases, product launches, leadership changes, economic policies, and geopolitical developments.
How do stock splits affect Medicamen Biotech Ltd's share price history?
Stock splits reduce the nominal price of Medicamen Biotech Ltd's shares by increasing the number of outstanding shares, which typically makes the stock more accessible to a broader range of investors. Although the total market value of the company remains unchanged after the split, the split can affect investor perception and liquidity, potentially influencing the share price in the longer term.
How do dividends impact the share price history of Medicamen Biotech Ltd?
Dividends can influence Medicamen Biotech Ltd's share price history by typically causing a temporary dip on the ex-dividend date, as the stock price often adjusts to reflect the dividend payout. Over time, the impact of dividends on the share price may be offset by the company's overall financial performance and market conditions.
How do corporate announcements affect Medicamen Biotech Ltd’s share price history?
Corporate announcements such as mergers, acquisitions, or strategic shifts can lead to significant price changes. Any optimistic development news on Medicamen Biotech Ltd generally boosts the company’s share price, whereas negative news can lead to a decline in share price.
How can I use technical analysis to understand Medicamen Biotech Ltd’s share price history?
To understand Medicamen Biotech Ltd’s share price history using technical analysis, examine charts for patterns such as trends, support, and resistance levels, and apply indicators like moving averages or Relative Strength Index (RSI) to gauge potential future movements. Analyze historical data to identify recurring trends and signals that might suggest how the share price could behave under similar conditions.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
